Department of Nuclear Medicine, Noordwest Ziekenhuisgroep, Alkmaar, The Netherlands; and
Department of Nuclear Medicine, Noordwest Ziekenhuisgroep, Alkmaar, The Netherlands; and.
J Nucl Med. 2018 Jul;59(7):1081-1084. doi: 10.2967/jnumed.117.207316. Epub 2018 Mar 1.
In the literature, a 4- to 6-h fast is recommended before a patient undergoes PET/CT with 2-(3-(1-carboxy-5-[(6-F-fluoro-pyridine-3-carbonyl)-amino]-pentyl)-ureido)-pentanedioic acid (F-DCFPyL); however, a scientific underpinning for this recommendation is lacking. Therefore, we performed a study to determine the impact of fasting on F-DCFPyL uptake. The study included 50 patients who fasted at least 6 h before F-DCFPyL administration and 50 patients who did not. Activity (SUV) was measured in lesions characteristic of prostate cancer and in normal tissues known to express high physiologic uptake. Uptake in suspected lesions did not differ between the cohorts. F-DCFPyL uptake in the submandibular gland, liver, and spleen was significantly higher in the fasting than the nonfasting cohort. Our data show that fasting does not significantly affect F-DCFPyL uptake in suspected malignant lesions but does result in significantly lower F-DCFPyL uptake in tissues with high physiologic uptake. The absolute differences in uptake were relatively small; therefore, the effects of fasting on the diagnostic performance can be considered negligible.
在文献中，建议在患者接受 2-(3-(1-羧基-5-[(6-F-吡啶并[3,2-d]嘧啶-3-羰基)-氨基]-戊基)-脲基)-戊二酸(F-DCFPyL)的 PET/CT 检查前禁食 4 至 6 小时；然而，缺乏对此建议的科学依据。因此，我们进行了一项研究，以确定禁食对 F-DCFPyL 摄取的影响。该研究纳入了 50 名在 F-DCFPyL 给药前至少禁食 6 小时的患者和 50 名未禁食的患者。在前列腺癌特征性病变和已知高生理摄取的正常组织中测量活性（SUV）。疑似病变中的摄取在两组间无差异。在颌下腺、肝脏和脾脏中，禁食组的 F-DCFPyL 摄取明显高于未禁食组。我们的数据表明，禁食不会显著影响疑似恶性病变中 F-DCFPyL 的摄取，但确实会导致高生理摄取组织中 F-DCFPyL 的摄取显著降低。摄取的绝对差异相对较小；因此，可以认为禁食对诊断性能的影响可以忽略不计。
